三阴性乳腺癌免疫治疗2021年度盘点

New progress in immunotherapy for triple negative breast cancer in 2021

乳腺癌是中国女性最常见的恶性肿瘤。乳腺癌的治疗是以手术、放射治疗、化疗、内分泌治疗、生物治疗等多学科协作的综合治疗。随着循证医学证据的积累,免疫治疗作为生物治疗的重要组成部分,应用越来越广泛。笔者回顾三阴性乳腺癌免疫治疗的研究现状,总结2021年三阴性乳腺癌免疫治疗年度研究进展,并对三阴性乳腺癌免疫治疗的研究和发展进行解读。

Breast cancer is the most common malignant tumor in Chinese women.The treatment of breast cancer is comprehensive treatment of surgery,radiotherapy,chemotherapy,endocrine therapy and biological therapy,requiring multidisciplinary cooperation.With accumulation of evidence-based practice,immunotherapy,as an important part of the biological therapy,is widely applied.We reviewed the current research of immunotherapy for triple negative breast cancer,summarized the relevant progress in 2021,and interpreted the advancement in this field.